Tag Archive for: Clinical Trial

Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer

/in

More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalation Advancement of ONA-255 marks an important milestone following Ona’s $86.6 million Series B financing Internationally recognized oncologist and physician-scientist Aleix Prat, MD, PhD, appointed Chief Medical Officer, as Jutta Amersdorffer, MD, MBA, […]

Read more

R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis

/in

AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients Study underway with first patient randomized in the global Phase 2b trial of AP306 conducted in partnership with Alebund in the US and China Study builds on positive Phase 2a […]

Read more

Poolbeg Pharma plc – First Patient Dosed in the POLB 001 TOPICAL Clinical Trial

/in

Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies Highlights ·    First patient dosed in the POLB 001 TOPICAL clinical trial ·    Second site, University College London Hospital, activated with patient recruitment underway ·    Additional clinical sites expected to open imminently, supporting continued patient recruitment 13 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or […]

Read more

Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

/in

First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability KIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF) KIT2014’s unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation   Turin, Italy […]

Read more

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

/in

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission to EMA for conversion to full marketing authorization planned for Q4 2026 Lund, Sweden, May 27, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: […]

Read more
© Optimum Strategic Communications.